A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-In-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma
media
posted on 2022-01-11, 12:48 authored by Adis Journals on behalf of, Dominic Brittain, Peter D’Andrea, Emilie Gruen, Motoi Hosoe, Devendra JainDevendra Jain, Juergen Jauernig, Abhijit Pethe, Emil Scosyrev, Ana-Maria Tanase, Hanns-Christian Tillman<p><strong>Article full
text</strong></p>
<p><br></p><p>
The above talking head video represents the opinions of
the authors. For a full list of declarations, including
funding and author disclosure statements, please see the full text online (see
“read the peer-reviewed publication” opposite). </p>
<p>© The authors, CC-BY-NC 2022.<b> </b></p>
History
Related Materials
- 1.
- 2.
